{'fraction_non_alphanumeric': 0.026054590570719603, 'fraction_numerical': 0.0024813895781637717, 'mean_word_length': 5.956896551724138, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].

First-line antihypertensive monotherapy is effective in normalizing blood pressure in approximatively 50 per cent of patients. Normalization in the remaining patients may require a combination of two or more drugs. This review considers the rationale and the evaluation of combinations with drugs interacting with the renin-angiotensin system (i.e. angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor antagonists) with other drugs. The combinations may be justified when giving an additive or synergistic action and when reducing clinical or metabolic side-effects. Recent developments concern the potential benefit of combining ACEI and angiotensin receptor antagonists.